- Marketwired•20 hours ago
GeoVax Labs, Inc. , a biotechnology company specializing in developing human vaccines, announced today that its Senior Vice President of Research and Development, Dr. Farshad Guirakhoo, will give a talk ...
- Marketwired•5 days ago
In recognition of World AIDS Day on December 1, GeoVax Labs, Inc. , a biotechnology company specializing in developing human vaccines, encourages everyone to get tested for HIV, the virus that causes AIDS....
- Zacks Small Cap Research•15 days ago
Total revenue was $440,106 for the three-month ended September 30, 2016, which was related to grants from the NIH in support of its HIV/AIDS vaccine development efforts. R&D expenses were $683,939 for 3Q16, as compared to $378,521 for the comparable period of 2015. R&D expenses included direct costs funded by NIH grants, as well as other vaccine manufacturing and testing costs. G&A expenses were $220,707 for the three month ended September 31, 2016, as compared to $335,932 for the comparable period of 2015.
GOVX : Summary for GEOVAX LABS INC COM STK USD0.01 - Yahoo Finance
GeoVax Labs, Inc. (GOVX)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.80|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|